Innovative Product Launch Orasis Pharmaceuticals has recently launched Qlosi, a novel eye drop for presbyopia, which is now available for prescription in the US, presenting a compelling sales opportunity within ophthalmology and eye care clinics seeking advanced presbyopia treatments.

Growing Financial Support With a substantial Series D financing of 78 million dollars and an additional 15 million dollars in structured capital, Orasis is financially positioned to expand its sales efforts and strengthen relationships with eye care professionals and healthcare providers.

Leadership Expansion Recent appointments of senior executives in sales and quality operations indicate an organizational focus on scaling distribution and ensuring high-quality product delivery, signaling readiness to engage with new partners and expand market reach.

Market Positioning As a focused ophthalmic company developing reformulated eye drops for presbyopia, Orasis is well-positioned to compete with emerging treatments and established players, highlighting opportunities for strategic partnerships and targeted sales campaigns.

Technology Adoption Utilizing advanced digital tools such as Zoom and Microsoft Teams, Orasis demonstrates a modern approach to healthcare engagement, providing a platform for virtual meetings, product demonstrations, and remote outreach with healthcare providers and stakeholders.